| |
Companion diagnostics play a vital role in oncology therapeutic development, but evolving regulations are changing the game. Join our webinar for expert guidance on adapting your assay development and study design strategies. Register to stay ahead! 
|
|
Today’s Big NewsJan 22, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now. 
|
|
| By Gabrielle Masson “There's an evolution of our economic model that starts with IRA, and will get worse and worse and worse, but I think there's so many opportunities for us to counter that with new ways of working,” R&D head Andy Plump, M.D., Ph.D., told Fierce Biotech at the annual J.P. Morgan Healthcare Conference. |
|
|
|
By Nick Paul Taylor A trio of Chinese biotechs have filed to go public, setting the stage for offerings that could fill the coffers of companies that have big deals with Bristol Myers Squibb and Takeda. |
By James Waldron Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. |
By Nick Paul Taylor Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other chronic conditions. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
By James Waldron A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing deals. |
By Kevin Dunleavy An observational study from Washington University in St. Louis has shed more light on the benefits—as well as the risks—of using new diabetes and weight loss drugs from Novo Nordisk and Eli Lilly. According to the study, researchers found that use of the new medicines may reduce the risk of Alzheimer’s disease and substance abuse disorders while increasing the risk of digestive issues and arthritis. |
By Dave Muoio The pharmacy chain dispensed “dangerous and excessive quantities," early refills of opioids and prescriptions for the especially dangerous and abused combination of drugs known as the ‘trinity," the DOJ said Friday. |
By Darren Incorvaia Clinical research tech firm Advarra has unveiled a new digital solution meant to help speed up study starts and facilitate collaboration between trial sponsors and research sites. |
By Fierce Healthcare Staff,Dave Muoio,Noah Tong,Emma Beavins,Anastassia Gliadkovskaya Alongside revoking 78 Biden executive orders, a busy first day for the Trump administration produced a government hiring freeze, withdrawals from global organizations, a revoked AI order, personnel changes and more. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the trends that defined the industry in 2024 and predict how 2025 might shake out for biopharmas big and small. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
